A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Melvin Heyman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics. Authored (or co-authored) 312 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT03345836
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated